Literature DB >> 21041313

CC chemokine receptor 5 (CCR5) desensitization: cycling receptors accumulate in the trans-Golgi network.

Jean-Michel Escola1, Gabriel Kuenzi, Hubert Gaertner, Michelangelo Foti, Oliver Hartley.   

Abstract

CC chemokine receptor 5 (CCR5), the major HIV coreceptor, is a G protein-coupled receptor (GPCR) involved in cell activation and migration in response to chemokines. Blockade of CCR5 is an effective anti-HIV strategy, and potent anti-HIV chemokine analogs such as PSC-RANTES have been developed. These inhibitors act by interfering with receptor trafficking, thereby inducing prolonged intracellular sequestration of CCR5. Like many GPCRs, CCR5 is desensitized following agonist activation. The initial steps in this process are well understood, but later stages, including where CCR5 is sequestered during desensitization, and how anti-HIV chemokine analogs intervene to achieve prolonged sequestration, have yet to be elucidated in detail. In this study we demonstrate that CCR5 cycles to and from the cell surface via the endosome recycling compartment and the trans-Golgi network during desensitization, accumulating in the trans-Golgi network following internalization by both PSC-RANTES and CCL5, the native ligand from which it was derived. In addition, we show that unlike CCR5 sequestered by CCL5, CCR5 sequestered by PSC-RANTES cannot be induced to return to the cell surface by addition of the small molecule CCR5 inhibitor, TAK-779, and that association of PSC-RANTES with CCR5 is more durable than that of native CCL5 during desensitization. Our findings reconcile the previously conflicting descriptions of the location of sequestered CCR5 during desensitization, as well as providing more general insights into potential trafficking routes for endocytosed GPCRs and further elucidation of the unusual inhibitory mechanism of chemokine analogs with potent anti-HIV activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21041313      PMCID: PMC3009905          DOI: 10.1074/jbc.M110.153460

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Activated somatostatin type 2 receptors traffic in vivo in central neurons from dendrites to the trans Golgi before recycling.

Authors:  Zsolt Csaba; Benjamin Lelouvier; Cécile Viollet; Vincent El Ghouzzi; Kiyoko Toyama; Catherine Videau; Véronique Bernard; Pascal Dournaud
Journal:  Traffic       Date:  2007-05-22       Impact factor: 6.215

Review 2.  Targeting chemokine receptors in HIV: a status report.

Authors:  Shawn E Kuhmann; Oliver Hartley
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

Review 3.  Regulation of GPCRs by endocytic membrane trafficking and its potential implications.

Authors:  Aylin C Hanyaloglu; Mark von Zastrow
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

4.  Agonist-induced endocytosis of CC chemokine receptor 5 is clathrin dependent.

Authors:  Nathalie Signoret; Lindsay Hewlett; Silène Wavre; Annegret Pelchen-Matthews; Martin Oppermann; Mark Marsh
Journal:  Mol Biol Cell       Date:  2004-12-09       Impact factor: 4.138

5.  Gamma-BAR, a novel AP-1-interacting protein involved in post-Golgi trafficking.

Authors:  Veronika E Neubrand; Rainer D Will; Wiebke Möbius; Annemarie Poustka; Stefan Wiemann; Peter Schu; Carlos G Dotti; Rainer Pepperkok; Jeremy C Simpson
Journal:  EMBO J       Date:  2005-03-10       Impact factor: 11.598

6.  Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines.

Authors:  A Trkola; W A Paxton; S P Monard; J A Hoxie; M A Siani; D A Thompson; L Wu; C R Mackay; R Horuk; J P Moore
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

Review 7.  G protein-coupled receptor sorting to endosomes and lysosomes.

Authors:  Adriano Marchese; May M Paing; Brenda R S Temple; JoAnn Trejo
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

8.  Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors.

Authors:  Oliver Hartley; Hubert Gaertner; Jill Wilken; Darren Thompson; Richard Fish; Alejandra Ramos; Cristina Pastore; Brigitte Dufour; Fabrice Cerini; Astrid Melotti; Nikolaus Heveker; Laurent Picard; Marc Alizon; Donald Mosier; Stephen Kent; Robin Offord
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-15       Impact factor: 11.205

9.  Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity.

Authors:  M Mack; B Luckow; P J Nelson; J Cihak; G Simmons; P R Clapham; N Signoret; M Marsh; M Stangassinger; F Borlat; T N Wells; D Schlöndorff; A E Proudfoot
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

10.  A syntaxin 10-SNARE complex distinguishes two distinct transport routes from endosomes to the trans-Golgi in human cells.

Authors:  Ian G Ganley; Eric Espinosa; Suzanne R Pfeffer
Journal:  J Cell Biol       Date:  2008-01-14       Impact factor: 10.539

View more
  29 in total

Review 1.  Mechanisms regulating chemokine receptor activity.

Authors:  Laura D Bennett; James M Fox; Nathalie Signoret
Journal:  Immunology       Date:  2011-11       Impact factor: 7.397

2.  HIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokines.

Authors:  Philippe Colin; Yann Bénureau; Isabelle Staropoli; Yongjin Wang; Nuria Gonzalez; Jose Alcami; Oliver Hartley; Anne Brelot; Fernando Arenzana-Seisdedos; Bernard Lagane
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-21       Impact factor: 11.205

3.  Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry.

Authors:  Jun Jin; Philippe Colin; Isabelle Staropoli; Evelyne Lima-Fernandes; Cécile Ferret; Arzu Demir; Sophie Rogée; Oliver Hartley; Clotilde Randriamampita; Mark G H Scott; Stefano Marullo; Nathalie Sauvonnet; Fernando Arenzana-Seisdedos; Bernard Lagane; Anne Brelot
Journal:  J Biol Chem       Date:  2014-05-22       Impact factor: 5.157

Review 4.  Intracellular α(2C)-adrenoceptors: storage depot, stunted development or signaling domain?

Authors:  Maqsood A Chotani; Nicholas A Flavahan
Journal:  Biochim Biophys Acta       Date:  2011-05-14

5.  Constitutive internalization of the leucine-rich G protein-coupled receptor-5 (LGR5) to the trans-Golgi network.

Authors:  Joshua C Snyder; Lauren K Rochelle; H Kim Lyerly; Marc G Caron; Lawrence S Barak
Journal:  J Biol Chem       Date:  2013-02-25       Impact factor: 5.157

6.  Corruption of human follicular B-lymphocyte trafficking by a B-cell superantigen.

Authors:  Gwenoline Borhis; Muriel Viau; Gamal Badr; Yolande Richard; Moncef Zouali
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

7.  Trans-Golgi Network (TGN) as a regulatory node for β1-adrenergic receptor (β1AR) down-modulation and recycling.

Authors:  Shi-Bin Cheng; Edward J Filardo
Journal:  J Biol Chem       Date:  2012-02-29       Impact factor: 5.157

8.  Combination of the CCL5-derived peptide R4.0 with different HIV-1 blockers reveals wide target compatibility and synergic cobinding to CCR5.

Authors:  Massimiliano Secchi; Lia Vassena; Sébastien Morin; Dominique Schols; Luca Vangelista
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191

9.  Downregulation of a GPCR by β-Arrestin2-Mediated Switch from an Endosomal to a TGN Recycling Pathway.

Authors:  Nazish Abdullah; Muheeb Beg; David Soares; Jeremy S Dittman; Timothy E McGraw
Journal:  Cell Rep       Date:  2016-12-13       Impact factor: 9.423

10.  Cytotoxic T cells swarm by homotypic chemokine signalling.

Authors:  Jorge Luis Galeano Niño; Sophie V Pageon; Szun S Tay; Feyza Colakoglu; Daryan Kempe; Jack Hywood; Jessica K Mazalo; James Cremasco; Matt A Govendir; Laura F Dagley; Kenneth Hsu; Simone Rizzetto; Jerzy Zieba; Gregory Rice; Victoria Prior; Geraldine M O'Neill; Richard J Williams; David R Nisbet; Belinda Kramer; Andrew I Webb; Fabio Luciani; Mark N Read; Maté Biro
Journal:  Elife       Date:  2020-10-13       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.